TNGX vs TSHA: fair value comparison
Tango Therapeutics, Inc. and Taysha Gene Therapies, Inc. · Updated 2026-10-19
TNGX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TSHA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TNGX currently ranks higher by quality score.
| TNGX | TSHA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $22.04 | $3.62 |
| 12-month range | $7.50–$32.90 | $3.51–$6.98 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #272 of 301 Healthcare | #273 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: TNGX fair value analysis · TSHA fair value analysis